M&T Bank Corp Sells 280 Shares of iShares Biotechnology ETF (NASDAQ:IBB)

M&T Bank Corp trimmed its holdings in shares of iShares Biotechnology ETF (NASDAQ:IBB) by 6.7% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 3,911 shares of the financial services provider’s stock after selling 280 shares during the period. M&T Bank Corp’s holdings in iShares Biotechnology ETF were worth $569,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. BNP Paribas Financial Markets increased its holdings in iShares Biotechnology ETF by 29.3% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,380,229 shares of the financial services provider’s stock worth $346,561,000 after acquiring an additional 538,899 shares in the last quarter. Commerce Bank raised its position in shares of iShares Biotechnology ETF by 1.8% during the 3rd quarter. Commerce Bank now owns 743,366 shares of the financial services provider’s stock valued at $108,234,000 after buying an additional 12,921 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund grew its position in iShares Biotechnology ETF by 32.9% in the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 663,000 shares of the financial services provider’s stock worth $96,533,000 after acquiring an additional 164,000 shares in the last quarter. Main Management ETF Advisors LLC raised its position in iShares Biotechnology ETF by 2.5% during the third quarter. Main Management ETF Advisors LLC now owns 593,370 shares of the financial services provider’s stock valued at $86,395,000 after purchasing an additional 14,535 shares during the period. Finally, Raymond James Financial Services Advisors Inc. boosted its holdings in shares of iShares Biotechnology ETF by 24.6% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 217,047 shares of the financial services provider’s stock worth $29,792,000 after purchasing an additional 42,822 shares during the period. Institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Stock Performance

NASDAQ:IBB opened at $137.66 on Wednesday. The stock’s fifty day moving average is $141.74 and its 200 day moving average is $142.40. iShares Biotechnology ETF has a fifty-two week low of $123.60 and a fifty-two week high of $150.57.

iShares Biotechnology ETF Cuts Dividend

The company also recently announced a dividend, which will be paid on Friday, December 20th. Stockholders of record on Tuesday, December 17th will be issued a $0.0624 dividend. The ex-dividend date is Tuesday, December 17th.

iShares Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.